Biohaven signs Regeneron supply deal to test BHV-1530 with Libtayo

Biohaven Ltd.
Regeneron Pharmaceuticals, Inc.

Biohaven Ltd.

BHVN

0.00

Regeneron Pharmaceuticals, Inc.

REGN

0.00
  • Biohaven entered a clinical supply agreement with Regeneron to test FGFR3-targeted ADC BHV-1530 with cemiplimab (Libtayo) in solid tumors.
  • Combination plan follows early Phase 1 monotherapy signals for BHV-1530, including tumor reductions in FGFR3-altered or wild-type overexpressing cancers.
  • Program aims to pair BHV-1530’s TopoIx payload with anti-PD-1 therapy, citing preclinical synergy and immunogenic cell-death activity.
  • Deal expands an existing supply arrangement between the companies tied to Biohaven’s TROP2-directed ADC BHV-1510.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biohaven Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607200730PR_NEWS_USPR_____NE07545) on July 20, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.